Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/48692
Type
PreprintCopyright
Open access
Collections
- BA - IGM - Preprint [86]
Metadata
Show full item record
SARS-COV-2 VARIANT OF CONCERN P.1 (GAMMA) INFECTION IN YOUNG AND MIDDLE-AGED PATIENTS ADMITTED TO THE INTENSIVE CARE UNITS OF A SINGLE HOSPITAL IN SALVADOR, NORTHEAST BRAZIL, FEBRUARY 2021 (PREPRINT)
SARS-CoV-2
Unidades de Terapia Intensiva
Pandemia
Rede Genômica Fiocruz
GENOMAHCOV
https://www.arca.fiocruz.br/handle/icict/50679
Author
Nonaka, Carolina Kymie Vasques
Gräf, Tiago
Barcia, Camila Araújo de Lorenzo
Costa, Vanessa Ferreira
Oliveira, Janderson Lopes de
Passos, Rogério da Hora
Bastos, Iasmin Nogueira
Santana, Maria Clara Brito de
Santos, Ian Marinho
Sousa, Karoline Almeida Felix de
Weber, Thamires Gomes Lopes
Siqueira, Isadora Cristina de
Rocha, Clarissa Araújo Gurgel
Mendes, Ana Verena Almeida
Souza, Bruno Solano de Freitas
Gräf, Tiago
Barcia, Camila Araújo de Lorenzo
Costa, Vanessa Ferreira
Oliveira, Janderson Lopes de
Passos, Rogério da Hora
Bastos, Iasmin Nogueira
Santana, Maria Clara Brito de
Santos, Ian Marinho
Sousa, Karoline Almeida Felix de
Weber, Thamires Gomes Lopes
Siqueira, Isadora Cristina de
Rocha, Clarissa Araújo Gurgel
Mendes, Ana Verena Almeida
Souza, Bruno Solano de Freitas
Affilliation
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / D'Or Institute for Research and Education (IDOR). Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Intensive Care Unit. Salvador, BA, Brazil.
São Rafael Hospital. Intensive Care Unit. Salvador, BA, Brazil.
São Rafael Hospital. Intensive Care Unit. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Clinical Laboratory. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Intensive Care Unit. Salvador, BA, Brazil.
São Rafael Hospital. Intensive Care Unit. Salvador, BA, Brazil.
São Rafael Hospital. Intensive Care Unit. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Clinical Laboratory. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Abstract
To evaluate changes in COVID-19 patients' characteristics occurring after the emergence of the SARS-CoV-2 variant of concern (VOC) P.1 (Gamma) by comparing the clinical, demographic and laboratory profile of patients hospitalized during the first (May-July 2020) and second (December 2020 - February 2021) pandemic waves. Methods: Data was collected from records of COVID-19 patients (n=4164) admitted to a single hospital in Salvador, Northeast Brazil. SARS-CoV-2 genome sequencing was performed in nasopharyngeal swab samples from 12 patients with age < 60 years-old admitted to the intensive care units (ICU) in February 2021. Results: From June 2020 to February 2021, the median age of patients admitted in the ICU decreased from 66 to 58 years (p<0.05), accompanied by an increased proportion of patients without comorbidities (15.32% vs 32.20%, p<0.0001). A significant reduction in the Ct values of SARS-CoV-2 RT-PCR tests was observed in the second wave (p<0.0001). Sequencing analysis detected lineage Gamma in all 12 ICU patients sampled in February 2021. Conclusion: Our results demonstrated an increased proportion of younger adults without comorbidities with severe disease during the second COVID-19 wave, shortly after the confirmation of local Gamma circulation.
Keywords in Portuguese
COVID-19SARS-CoV-2
Unidades de Terapia Intensiva
Pandemia
Rede Genômica Fiocruz
GENOMAHCOV
Share